THE DOSE The peptide market decoded — science, signal, and BS detection for the biohacking era. Tuesday, March 24, 2026

COMPOUND WATCH

BPC-157 [Animal → Phase 2 🆕] The most-injected peptide with zero human RCTs just crossed a threshold. NCT07437547 — BPC-157 for Acute Hamstring Muscle Strain Repair — is actively recruiting as of February 2, 2026. Phase 2. Real IRB. Real endpoints. The endpoint is narrower than the community's use cases (gut healing, systemic anti-inflammatory, tendon repair broadly) — but human safety and PK data from this trial will be the first real signal on whether the rat data translates at all. The Phase 2 trial used pharmaceutical-grade compound. Your gray-market vial may not be the same thing.

Evidence grade: [Animal] → [Phase 2 — recruiting]. Zero published human RCTs. Still injected by hundreds of thousands. The gap is narrowing — but it's still a gap.

AMP Peptide 'LR' — Ulcerative Colitis [Animal/In Vitro] 🆕 For the subset of this readership using BPC-157 for GI applications: this is the pipeline to watch. A machine learning-accelerated discovery study from Jilin University (published in eGastroenterology) screened 6,000+ antimicrobial peptide candidates, identified 22 promising sequences, synthesized 5. Peptide 'LR' showed the strongest bactericidal activity against E. coli, reduced TNF-α and IL-6, restored intestinal barrier integrity via ZO-1 tight junction proteins, and significantly increased Akkermansia muciniphila abundance in colitis mice. Preclinical only — no human translation yet. Not sourceable. Not actionable today. But this is what a legitimate mechanistic alternative to BPC-157 for gut healing looks like at the animal stage. [Animal/In Vitro]. File it.

Retatrutide [Phase 3] Lilly's triple agonist (GIP/GLP-1/glucagon) continues to dominate pipeline coverage. Phase 3 TRANSCEND-T2D-1 data: 15.3–16.8% body weight loss and 1.9–2.0% A1C reduction at 40 weeks across 537 participants. The numerical spread reflects efficacy vs. treatment-policy estimand differences — not a discrepancy. Scotiabank: "highest levels of weight loss we've seen from an obesity drug to date." J.P. Morgan projects the global incretin market at $200B by 2030. Seven additional Phase 3 trials ongoing. Full data at ADA Scientific Sessions, June 2026.

Wegovy HD (semaglutide 7.2mg) [Phase 3 → FDA approved] FDA approved in 54 days under the Commissioner's National Priority Voucher pilot — the 4th approval under this program. New AE to flag: altered skin sensation (burning, sensitivity, pain) in addition to standard GI effects. Incidence rate not yet published in public-facing trial data — monitor the full label when it posts. If you're on 2.4mg and plateauing, your prescriber can now write for 7.2mg. Access is the next question.

Setmelanotide / IMCIVREE [Phase 3 → FDA approved, new indication] MC4R agonist peptide approved for acquired hypothalamic obesity — broad label, no post-marketing commitments. 18.4% placebo-adjusted BMI reduction at 52 weeks in 142 patients. ~10,000 U.S. patients estimated eligible. Not a gray-market compound, but mechanistically relevant to anyone researching melanocortin pathway peptides.

VENDOR SIGNAL

No new Finnrick rating changes, failed HPLC results, or Janoshik test disclosures surfaced in today's data. No new FDA warning letters targeting specific peptide vendors or compounding pharmacies were issued March 21–24.

For GLP-1 compounders: The Hims capitulation (see REGULATORY RADAR) removes one of the largest telehealth platforms from the compounded GLP-1 market. Empower and Olympia remain the dominant 503B players — no new quality or enforcement flags on either today. If you're sourcing compounded semaglutide through any telehealth platform, verify their 503B status before your next fill.

Why 503A exposure is higher for GLP-1 specifically: 503A pharmacies can only compound for individual patient prescriptions — they cannot produce GLP-1 batches in advance or sell to practitioners without a patient-specific Rx. That makes their GLP-1 production harder to defend as legitimate compounding under current FDA enforcement posture, which is targeting bulk production and telehealth-scale distribution. 503B facilities can produce office-use batches. That's the structural difference.

For gray-market vendors (QSC, SRY, GYC): No new data on operations, customs seizures, or independent purity testing today. [COA Only] remains the default grade for all three until independent HPLC verification surfaces. Check finnrick.com before your next order.

Reminder: 15–20% of supplier COAs show discrepancies when independently verified. If you're injecting BPC-157 from a source with no third-party HPLC on file, you're running on trust, not data.

[Unverified] — QSC, SRY, GYC: No new independent test data today. [COA Only] — Most U.S. research peptide vendors: self-reported purity, not independently confirmed. [Flagged — prior] — GenoGenix: bacterial endotoxin contamination, FDA action on record.

TRIAL TRACKER

NCT07437547 — BPC-157, Phase 2, Hamstring Muscle Strain | Recruiting First controlled human trial for the most popular gray-market peptide on the planet. If you're currently dosing BPC-157, the interim safety and PK data from this trial — expected 12–18 months out — is the most important piece of science you'll read in 2027. Enrollment pace is worth tracking: fast enrollment signals institutional confidence in the compound.

NCT07232719 / NCT07357415 — Retatrutide Phase 3, Obesity/Overweight | Recruiting Two of seven active Phase 3 retatrutide trials are actively enrolling. Per-week weight loss comparison, shown explicitly: Retatrutide is running at approximately ~0.38–0.42% body weight per week at 40 weeks. Tirzepatide's ~20–22% at 72 weeks works out to approximately ~0.28–0.31% per week. Caveat: longer trials tend to show slower per-week rates as plateau effects accumulate — so this comparison favors retatrutide partly by design. The 72-week retatrutide maintenance data (NCT06859268, active not recruiting) will be the real test. ADA June presentation is the first full public readout.

NCT06632444 — Survodutide (BI 456906), Phase 3, MASH/Liver Fibrosis | Recruiting GLP-1/glucagon dual agonist for metabolic dysfunction-associated steatohepatitis. If you're using GLP-1s for metabolic health broadly — not just weight — MASH is where the next major approval battle is being fought. LIVERAGE Phase 3 data will define whether GLP-1 class effects extend meaningfully into liver fibrosis reversal.

THE ODDS

Polymarket signals translated for peptide practitioners.

INFLATION: 98% probability >3% in 2026 ($206K volume) At 98%, this isn't a prediction — it's a pricing assumption. Compounding pharmacies pass input cost increases through within 60–90 days. Model your tirzepatide vial at current price × 1.05–1.08 by Q3. The gray-market channel is more exposed: Chinese API costs are dollar-denominated, and domestic logistics and testing costs in China are rising regardless of currency moves. Budget for price creep in both channels.

FED RATE CUTS: 30% probability of zero cuts in 2026 ($2.4M volume — highest signal here) Seven-in-ten chance of at least one cut. If rates stay elevated, the telehealth platforms that borrowed to scale face continued margin pressure — accelerating the pivot toward branded pharma partnerships (see Hims-Novo) rather than compounding. If "no cuts" probability drifts above 50%, expect more Hims-style capitulations. That reshapes compounded GLP-1 access faster than any single FDA enforcement action.

RECESSION: 34% probability by end of 2026 ($808K volume) Below the threshold where I'd change sourcing behavior — as a rule of thumb, I'd watch above ~45% before shifting meaningfully toward gray-market to cut costs. At 34%, the more relevant dynamic is counterintuitive: people losing employer coverage migrate to self-pay compounding channels. Mild recession risk is a tailwind for compounding volume, not a headwind.

TARIFFS: 1% probability of Trump tariff dividend by March 31 ($145K volume) The dividend is noise. The underlying tariff structure is not. A 25% tariff on Chinese goods remains the live structural risk — not an imminent announcement. No formal tariff escalation on pharma inputs confirmed today. The asymmetry to manage: if a tariff escalation targeting API is announced, you'll have days not weeks to adjust sourcing. That's a reason to have a contingency plan, not a reason to place emergency orders today.

SIGNAL VS. NOISE

SIGNAL: Stopping GLP-1s = 22% higher cardiovascular event risk Study of 333,000+ U.S. veterans: discontinuing GLP-1s linked to a 22% increase in heart attack, stroke, and death over two years. Cleveland Clinic data: 19.6% restarted the same GLP-1 within one year; 35.2% received alternative treatment. This is the number that should drive urgency if the Hims channel change forces you off compounded semaglutide — not the inconvenience. The access disruption risk has a quantified health cost. Find a replacement source before you're forced to stop, not after.

SIGNAL: Hims & Hers folds to Novo — compounded GLP-1 channel narrows Becker's ASC, March 23: Hims will now offer FDA-approved Ozempic injections AND Wegovy (injectable + tablet) through its platform by end of March. Under the deal, Hims stops advertising compounded GLP-1s. This followed Novo's patent infringement lawsuit (filed the same day Hims launched its $99/month compounded Wegovy pill), an HHS referral to the DOJ, and Hims pulling the product within days. The compounded GLP-1 access channel is measurably narrower today than it was 60 days ago.

SIGNAL: India generic semaglutide — 15+ brands, 70–90% price crash, $1.59 oral tablet Reuters, March 23 and Business Standard, March 22: Sun Pharma (₹3,000–8,000/month), Zydus (~₹2,200/month), Glenmark (₹1,290–1,760/month), Torrent oral tablet (₹149/tablet ≈ $1.59 USD). 40+ companies and 50+ brands expected. Indian manufacturers are eyeing Canada, Brazil, Latin America, Turkey for future launches. There is currently no legal U.S. sourcing pathway for these generics. Customs seizure risk is high. But ₹149/tablet is a global pricing reference point that makes U.S. compounding margins look very different — and will accelerate gray-market import demand regardless of legal status.

SIGNAL: GLP-1 + 6–8 healthy habits = 43% lower cardiovascular event risk ScienceAlert/AP, March 24: Study of 98,000 U.S. military veterans. GLP-1 + 6–8 healthy habits vs. no drug + ≤3 habits = 43% lower risk of serious cardiovascular events. This isn't a soft lifestyle recommendation — it's a mechanistic finding with a large sample. If you're on tirzepatide or semaglutide and skipping resistance training, you're leaving the most significant part of the risk reduction on the table. Protein target: 20–30g per meal. Exercise: 150 min aerobic/week + 30 min strength 2–3x/week.

SIGNAL: Amazon Pharmacy adds Zepbound 2.5mg at $299/month, same-day delivery BBC, March 23: Amazon Pharmacy now offers Zepbound 2.5mg KwikPen at $299/month with same-day delivery in ~3,000 cities, expanding to 4,500 by end of 2026. Wegovy starting dose is now $149/month self-pay. These are direct competitive pressure points on compounding pharmacies — not hypothetical. If you're paying more than $299/month for compounded tirzepatide and compliance (not cost) is your issue, the Amazon channel now exists.

NOISE: GLP-1 drugs reduce brain metastasis mortality (JAMA Network Open) 19,000+ cancer patients, GLP-1 users significantly less likely to die during the study period. The mechanism is plausible — GLP-1 receptors in brain tissue, anti-inflammatory effects. But this is a retrospective observational study. Confounding is enormous: GLP-1 users may simply be healthier, more engaged patients overall. Do not change your oncology protocol based on this. [Anecdotal-adjacent] until a prospective trial exists.

NOISE: MLPH peptide for hair growth (DGIST, South Korea) Novel peptide targeting EPO receptor in hair follicle cells, tested on human hair follicle tissue and animal models. No clinical trials. No side effects observed in preclinical. [Animal/In Vitro]. Not injectable. Not sourceable. Not actionable. Watch for gray-market vendors creating "MLPH peptide" listings within 90 days — that's when you'll need this grade tag.

REGULATORY RADAR

Hims-Novo deal: the template is set The mechanism matters more than the headline. Novo filed a patent infringement lawsuit the same day Hims launched its $99/month compounded Wegovy pill. HHS referred Hims to the DOJ. Hims pulled the product within days. Now Hims is a Novo distribution partner. Three words: litigate, refer, convert. Expect Lilly to run the same play against any telehealth platform that scales compounded tirzepatide. The 30 prior FDA warning letters were warnings. The Hims DOJ referral was escalation. The deal is the resolution template. For your sourcing decision: telehealth platforms offering compounded GLP-1s below branded price are now operating with a visible legal target on them. Novo is defending hard: the company is guiding -5% to -13% sales decline in 2026 and trading at $36.49 / 10.35x earnings — a significant discount to Lilly. That's a company with its back against the wall on compounding competition.

RFK peptide reclassification: still enforcement discretion only No Federal Register notices, no HHS announcements, no formal FDA reclassification actions on Category 2 peptides (BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu) in today's data. Status unchanged. RFK promised to reclassify ~14 of 19 Category 2 peptides back to Category 1 — which would reopen compounding for all of the above. As of March 24, 2026: no formal rule, enforcement discretion only. Your compounder is operating on regulatory goodwill, not legal protection. Set a Google Alert for "Category 2 peptide reclassification Federal Register" — that notification matters more than any single vendor rating.

503B landscape: 72 registered facilities No new closures confirmed today. The Hims deal and ongoing warning letter campaign signal that FDA is actively reshaping who can participate in the compounded GLP-1 market. If your compounder is a 503A, they face higher legal exposure for GLP-1 production than a 503B — for the structural reason explained in VENDOR SIGNAL above.

WHAT TO WATCH

April 10 — Orforglipron FDA PDUFA date. Know the efficacy data before the pricing announcement drops. Phase 3 Lancet data (1,698 T2D adults, 131 centers): 6–8% body weight reduction at 52 weeks — lower than tirzepatide's ~20–22% at 72 weeks, but the key structural advantage is no fasting required for absorption (unlike oral semaglutide). If you're on injectable tirzepatide and compliance is the issue, orforglipron's convenience profile matters more than the efficacy gap. Then watch Lilly's pricing announcement within 24 hours of approval. Above ~$400/month self-pay = compounded tirzepatide/semaglutide demand structurally intact. Below $300/month = ask your compounder what their capacity pivot looks like. That number is the signal.

By end of March — Hims branded GLP-1 pricing goes live. First pricing data from the Novo-Hims channel will be visible. Compare against Wegovy's current $149/month self-pay starting dose. If Hims prices above $149, it's a margin play. At or below, Novo is prioritizing volume over margin in the telehealth channel — which changes the competitive calculus for every compounder still in this market.

June 2026 — ADA Scientific Sessions: Full retatrutide Phase 3 TRANSCEND data. The 72-week and maintenance data will determine whether retatrutide displaces tirzepatide as the standard of care. The per-week efficacy advantage is real but the plateau data is what matters for long-term protocol decisions.

Ongoing — BPC-157 Phase 2 (NCT07437547). Monitor enrollment pace as a proxy for institutional confidence. Interim safety and PK data is 12–18 months out — but that data will be the first human evidence this compound has ever generated. If you're currently dosing BPC-157, this is the most important trial in your stack.

Ongoing — India generic semaglutide gray-market import channels. No confirmed U.S. sourcing pathway has emerged. Customs seizure risk remains high. But ₹1,290/month (~$13.74 USD) injectable semaglutide is now a real price in the world. Track whether any U.S.-based forwarding services or gray-market vendors begin listing Indian generics within the next 30–60 days. That's when customs seizure data will start to matter.

The line that matters this week: Hims just showed you the playbook — litigate, refer, convert. The compounded GLP-1 window is closing from the top. The gray-market window has a tariff clock running from the bottom. The 22% cardiovascular risk increase from stopping GLP-1s means the cost of an access disruption isn't just financial. The middle — verified 503B compounders with clean endotoxin records — is where the durable access lives. And if you're on BPC-157 for gut healing, the AMP 'LR' preclinical data is the first legitimate mechanistic alternative to appear in the pipeline. File it now; you'll want the reference in 18 months.

SCORECARD

Yesterday's prediction: India semaglutide patent expiry window (March 20–24) — medium confidence. ✓ Confirmed and exceeded. Patent expired March 20. 15+ generics launched within 48 hours. Pricing more aggressive than projected (70–90% crash vs. our 60–70% estimate). New data point not in yesterday's model: Torrent's oral semaglutide at ₹149 (~$1.59 USD) — the oral format changes the import-risk calculus for gray-market demand.

Ongoing prediction: India generic U.S. gray-market import channels. No confirmed U.S. sourcing pathway has emerged. Watch for U.S.-based forwarding services or gray-market vendor listings within 30–60 days.

Upcoming: April 10 — Orforglipron FDA decision. Binary. Approval likely (Phase 3 Lancet data published, 131-center trial). The pricing announcement within 24 hours is the signal — not the approval itself.

Reply to this email with feedback, sourcing questions, or a compound you want graded. I read every reply.

Stay curious, stay skeptical. — The Dose

Like what you're reading? Upgrade to Premium for early-access signals, weekly deep-dives, and the full 12-month archive. Founding members: $15/month. Manage your subscription.